Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus PYOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus PYOPEN.
PENICILLIN-2 vs PYOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
4 g intravenously every 4 hours.
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic